Gufic Biosciences Limited (BOM:509079)
India · Delayed Price · Currency is INR | Market Cap | 31.89B -12.4% |
| Revenue (ttm) | 8.97B +10.8% |
| Net Income | 500.38M -39.0% |
| EPS | 4.99 -39.0% |
| Shares Out | 100.28M |
| PE Ratio | 63.76 |
| Forward PE | n/a |
| Dividend | 0.10 (0.03%) |
| Ex-Dividend Date | Sep 22, 2025 |
| Volume | 4,636 |
| Open | 323.20 |
| Previous Close | 318.00 |
| Day's Range | 313.85 - 328.65 |
| 52-Week Range | 267.50 - 409.00 |
| Beta | -0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 29, 2026 |
About Gufic Biosciences
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P... [Read more]
Financial Performance
In fiscal year 2025, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.
Financial StatementsNews
Gufic Biosciences Transcript: Q3 25/26
Q3 FY26 saw flat sequential revenue and margins, with export growth offset by domestic operational changes and debtor corrections. Indore ramp-up and regulatory approvals are set to drive 15%+ growth and margin expansion in FY27, with export revenue from Europe expected to begin in Q3/Q4.
Gufic Biosciences Quarterly report: Q3 2026
Gufic Biosciences has published its Q3 2026 quarterly earnings report on February 16, 2026.
Gufic Biosciences Slides: Q3 2026
Gufic Biosciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 16, 2026.
Gufic Biosciences Transcript: Q2 25/26
Revenue and margins improved sequentially, driven by Indore facility ramp-up and strong international growth. Indore contributed all incremental revenue, with capacity utilization at 23-25%. CMO and domestic segments are set for further growth as more clients transition and new products launch.
Gufic Biosciences Quarterly report: Q2 2026
Gufic Biosciences has published its Q2 2026 quarterly earnings report on November 17, 2025.
Gufic Biosciences Slides: Q2 2026
Gufic Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 17, 2025.
Gufic Biosciences Transcript: Q1 25/26
Revenue grew 10% sequentially to INR 226.96 crore, driven by the Indore facility ramp-up and strong export momentum. EBITDA and profit margins improved, with further gains expected as capacity utilization and exports increase. Indore is set to become a margin accretive asset from FY 2027.
Gufic Biosciences Quarterly report: Q1 2026
Gufic Biosciences has published its Q1 2026 quarterly earnings report on August 14, 2025.
Gufic Biosciences Slides: Q1 2026
Gufic Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 14, 2025.
Gufic Biosciences Transcript: Q4 24/25
Revenue and EBITDA grew modestly year-over-year, but margins declined due to higher fixed costs from the new Indoor facility. International and botulinum toxin businesses are set for strong growth, with Indoor expected to reach EBITDA break-even in FY26 and full ramp-up by FY28.
Gufic Biosciences Annual report: Q4 2025
Gufic Biosciences has published its Q4 2025 annual report on June 2, 2025.
Gufic Biosciences Quarterly report: Q4 2025
Gufic Biosciences has published its Q4 2025 quarterly earnings report on June 2, 2025.
Gufic Biosciences Slides: Q4 2025
Gufic Biosciences has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on June 2, 2025.